key: cord-1038586-sxm9wu9u
authors: Smieszek, Sandra P.; Polymeropoulos, Mihael H.
title: Loss of Function Mutations in the IFNAR2 in COVID-19 Severe Infection Susceptibility
date: 2021-07-15
journal: J Glob Antimicrob Resist
DOI: 10.1016/j.jgar.2021.06.005
sha: 41d40cc6aec9d10397343a04ad66add98de08766
doc_id: 1038586
cord_uid: sxm9wu9u

Recent COVID-19 host genetic studies suggest enrichment of mutations in genes involved in the regulation of type I and type III IFN immunity in patients with severe COVID-19 infection. We have performed whole-genome sequencing analysis on samples obtained from patients participating in an ongoing ODYSSEY phase 3 study in hospitalized patients with severe COVID-19 receiving supplemental oxygen support. We focused on burden testing of categories of rare, and more common loss-of-function variants in all the IFN pathway genes specifically MAF<0.1% and MAF<1%. In MAF<1% in a model including LOFs and missense variants burden testing we see a significant signal on MAF<1% with both INFAR1 and IFNAR2. We report carriers of rare variants in our COVID-19 cohort, including a stopgain IFNAR2 (NM_000874:exon9:c.C966A:p.Y322X) amongst carriers of several other IFNAR rare nonsynonymous variants. Furthermore, we report increased allelic frequency of common IFNAR2 variants in our data, reported also by COVID-19 initiative.

COVID-19 receiving supplemental oxygen support. We focused on burden testing of categories of rare, and more common loss-of-function variants in all the IFN pathway genes specifically MAF<0.1% and MAF<1%. In MAF<1% in a model including LOFs and missense variants burden testing we see a significant signal on MAF<1% with both INFAR1 and IFNAR2. We report carriers of rare variants in our COVID-19 cohort, including a stopgain IFNAR2 (NM_000874:exon9:c.C966A:p.Y322X) amongst carriers of several other IFNAR rare nonsynonymous variants. Furthermore, we report increased allelic frequency of common IFNAR2 variants in our data, reported also by COVID-19 initiative.

Innate interferons (IFNs α/β and λ) play a major role in the induction and amplification of a crucial antiviral program in response to viral infections. Specifically, Type I IFNs play a crucial role in early-phase antiviral defense whereas cytokines/chemokines are associated with induction of later inflammatory responses and cytokine storm 1 The high-affinity interferon-α/β receptor IFNAR2 -/-genotype is associated with higher Influenza A Viral (IAV) infection, but decreased susceptibility to bacterial superinfection post IAV infection 4 . A recent study reported 50 COVID-19 patients with significantly impaired type I IFN activity, suggesting type I IFN deficiency in the blood may be a hallmark in severe COVID-19 patients 1 .

We have performed whole genome sequencing analysis on samples obtained from patients participating in ongoing ODYSSEY phase 3 randomized study of tradipitant and placebo in hospitalized patients with severe COVID-19 who are receiving supplemental oxygen support. The cohort was multiethnic and the age ranged from 35-87 for severe hospitalized COVID-19 cases (68% male, 32% female). We first focused on loss-of-function variants (rare pLOF) in all the IFN genes as described in Zhang et al. We performed burden testing of categories of rare loss-of-function variants in all the IFN pathway genes specifically MAF<0.1% and MAF<1%. Whereas we do not detect and pLOFs in the MAF<0.1% category, in MAF<1% in a model including LOFs and missense variants, we see a significant signal on MAF<1% with both INFAR1 and IFNAR2 as shown in Table 1 .

We report carriers of these variants in our COVID-19 cohort, ( are female, survivors, over 75 years old (plasma IFN-gamma levels 9.6pg/mL and BLQ). We show the key rare pLOFs and missense variants in Figure 1 . Furthermore, we report increased allelic frequency on common IFNAR2 variants in our data, reported also by COVID-19

initiative. We specifically focused on rs12482556 reported as second highest significant signal in the latest COVID19 initiative results 5 . In our cohort we report a global MAF of 0.44 versus 0.32 in our 1000g controls as well as gnomAD global MAF of 0.31. Variants detected have previously been associated with risk for susceptibility to hepatitis b (rs2229207) and susceptibility to herpes simplex encephalitis (rs151272128). For rs2229207 we show the respective levels of interferon gamma across genotypes (S. Figure 1 ) with minor allele showing lower levels of interferon gamma.

IFNAR2 LOF mutations including Tyr322Ter may increase susceptibility to severe COVID-19 infection especially among Asian descent populations where the mutation is more prevalent. We also make the observation that the IFNAR2 Tyr322Ter homozygous state may explain the increased mortality associated with MMR vaccination in Japan which led to the discontinuation of the triple live attenuated virus vaccinations in that country 6 . Notably, IFNAR2

LOF mutation was reported in young child with post MMR vaccination encephalitis 6 . Given that high-affinity IFNAR2 as well as components of its downstream signaling TYK2 and STAT1 and 

WGS cohort consisted of 80 COVID-19 hospitalized patient samples and 1876 WGS controls.

DNA was extracted from 200 µl of whole blood using QIAamp blood mini kit and eluted into 100 µl volume in order to obtain 500 ng of DNA. Libraries were prepared by random fragmentation of DNA followed by adapter ligation using Illumina TruSeq adapters. Paired-end libraries 2x150 bp were sequenced on an Illumina NovaSeq6000 S4 with a target of 90Gb raw read depth per sample. The cohort was multi-ethnic and the age ranged from 35-87 for severe hospitalized COVID-19 cases (68% male, 32% female). Furthermore, 16% of the cohort were patients hospitalized on mechanical ventilation or ECMO, 13% deceased.

Both cases and controls were processed with the same bioinformatic pipeline for variant calling.

Paired-end 150 bp reads were aligned to the GRCh37 human reference (BWA-MEM v0.7.8) followed by Picard (MarkDuplicates) and processed with GATK best-practices workflow (GATK v3.5.0). The mean coverage was 35.8x. All high quality variants obtained from GATK were annotated. Annotations include variant effect predictions using VEP; allele frequencies from Gnomad;dbSNP 150 rsIDs; conservation scores from PhyloP, GERP, PhastCons; damaging effect predictions from Polyphen 2, SIFT and clinically relevant information from ClinVar. We removed samples with a discordance between self-declared and sequence-derived gender, we used KING for detection of related individuals and performed PCA for ancestry adjustment.

Using the gene list tested by Zhang et al. we performed a gene set-based analysis to test for a significant difference in the proportion of cases carrying at least one qualifying variant in the gene set compared to controls focusing on rare missense variants (MAF<0.1%) as well as missense with MAF<1%. 

Clinical significance of measuring serum cytokine levels as inflammatory biomarkers in adult and pediatric COVID-19 cases: A review

Inborn errors of type I IFN immunity in patients with life-threatening COVID-19

Presence of Genetic Variants among Young Men with Severe COVID-19

IFNAR2 is required for anti-influenza immunity and alters susceptibility to post-influenza bacterial superinfections

The COVID-19 Host Genetics Initiative , a global initiative to elucidate the role of host genetic factors in susceptibility and severity of the SARS-CoV-2 virus pandemic

Human IFNAR2 deficiency: lessons for antiviral immunity Europe PMC Funders Group

The Role of Type I Interferons in the Pathogenesis and Treatment of COVID-19